Norbert Kiss, president and CEO of Circularity, says, “We believe people should have access to a single medical device that solves a majority of the short- and long-term health issues quickly and without pain.” This led the company to develop a first-of-its-kind biotech solution—D’OXYVA (deoxyhemoglobin vasodilator)—a non-irritating, painless, microcirculatory solution that improves blood flow, which subsequently leads to faster healing of wounds. “Our solution provides a gentle vapor of supersaturated CO2 and water that acts as a catalyst for the body to heal and improve itself,” affirms Dr. Paul Kirkitelos, CFO and business development officer of Circularity. D’OXYVA has been reviewed, clinically studied, and used by some of the prestigious healthcare institutions around the world.
Evidence from years of several highly successful clinical trials indicate that D’OXYVA could help significantly lower the risk of diabetes and cardiovascular complications; improve athletic performance, stamina, and sleep quality; and aid in maintaining skin health. “The solution has also recorded instant and sustained improvements in the autonomic nervous system (ANS), enhanced tissue perfusion, and superior blood macro- and micro-circulation,” adds Dr. Kirkitelos. D’OXYVA is delivered via a patented non-invasive transdermal delivery system—a small, portable, handheld device—and each application takes only five minutes.
D’OXYVA is a non-irritating, painless, microcirculatory solution that improves blood flow, which subsequently leads to faster healing of wounds
The supersaturated medical vapor produced by the system can be administered either by inserting the thumb into the device or gently spraying it on the skin.
“Patients that used D’OXYVA reported quicker wound treatments, lower instances of pain and infection, and faster recovery from trauma,” states Dr. Kirkitelos. Supporting this statement, he cites a case study involving a 62-year-old patient experiencing neuropathic pain, high blood pressure, and diabetic and cardiovascular complications. Due to his severe health conditions, the patient developed open wounds in the lower extremities of his body, which slowly spread and became chronic. Doctors tried every possible solution to cure the patient but were unsuccessful. Stepping into the picture, Circularity provided the patient with D’OXYVA. After using it two times a day for a couple of weeks, the patient was able to walk, his blood pressure reduced by 20-25 points, and all of his wounds healed completely. “This is just one example of how our solution accelerates the treatment of wounds,” replies Dr. Kirkitelos.
Over the years, Circularity has garnered massive consumer and client bases across the U.S., European, and Asian markets. The company also works with pharmaceutical gas providers such as Airgas—the largest producer of FDA-approved (USP) pharma-CO2—to bolster Circularity’s global growth. “The partnership allows Circularity to launch D’OXYVA in hospitals across the U.S. and many other countries,” adds Dr. Kirkitelos. In the days to come, the company is preparing to roll out its product in the Indian market. “We are also set to start clinical trials at leading U.S. research universities under contract, to demonstrate the potential of our solution in rapidly improving bone healing for patients suffering from osteoarthritis,” concludes Kiss. The company is focused on changing the standard of care and improving the dynamics of how the drug is delivered.